Payment & Shipping Terms:
32940 15 1
CAS No. : 165950-84-5 Rotigotine Intermediate GMP condition
Chemical Name : ( S ) - 6 - ( Propylamino ) - 5 , 6 , 7 , 8 - tetrahydronaphthalen - 1 - ol hydrobromide
CAS No . : 165950-84-5
Synonyms : ( S ) - 5 , 6 , 7 , 8 - Tetrahydro - 6 - ( propylamino ) - 1 - naphthalenol HBr ; ( 6S ) - 6 - ( propylamino ) - 5 , 6 , 7 , 8 - tetrahydronaphthalen - 1 - ol hydrobromide ; ( 6S ) - 6 - ( propylamino ) - 5 , 6 , 7 , 8 - tetrahydronaphthalen - 1 - ol HBr
Molecular Formula : C13H19NO . HBr ; C13H20BrNO
Molecular Weight : 286.21
Usage : Rotigotine Intermediate
Description: Rotigotine is the active pharmaceutical ingredient (API) of branded drug Neupro. The developing history of Rotigotine is quite long. It was developed in 1985 by University of Groningen. Aderis Pharmaceuticals continued its development. A German company called Schwarz Pharma (now a subsidiary of UCB S.A.) got worldwide development and commercialization rights from Aderis in 1998. Rotigotine is used to treat Parkinson’s disease (PD) and restless legs syndrome (RLS). Rogitine is maybe also useful to treat depression. Rogotine (Neupro) was approved by EMEA in Europe in 2006 and by FDA in USA in 2007.
( S ) - 6 - ( Propylamino ) - 5 , 6 , 7 , 8 - tetrahydronaphthalen - 1 - ol hydrobromide CAS No . : 165950-84-5 is one of its intermediates. There are several synthesis routes to manufacture this intermediate but some are protected by the patents in some countries or areas. We strictly obey the laws. The buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of the patent infringement by themselves.
Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.